- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 179 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 130 Pages
North America
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 119 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2022
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- December 2021
- 209 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- February 2024
- 140 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- April 2023
- 130 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- April 2024
- 500 Pages
Global
From €3864EUR$4,065USD£3,246GBP

Radium-223 is a radioactive isotope of radium used in nuclear medicine and radiopharmacology. It is used to treat prostate cancer that has spread to the bones, as it emits alpha particles that can kill cancer cells while sparing healthy tissue. Radium-223 is administered intravenously and is typically used in combination with other treatments such as hormone therapy.
Radium-223 is produced in nuclear reactors and is available in a variety of formulations. It is typically supplied as a solution in a vial, which is then further diluted for administration. The shelf life of the product is typically short, and it must be stored and handled in accordance with safety regulations.
The market for Radium-223 is relatively small, but it is growing as the demand for treatments for prostate cancer increases. Companies in the market include Algeta, Bayer, and Advanced Accelerator Applications. Show Less Read more